When incubated with human liver microsomes, 2-diethylaminoethyl-2,2-diphenylvalerate-HCl (SKF525A) undergoes cytochrome P450 (P450)-dependent oxidative N-deethylation to the secondary amine metabolite 2-ethylaminoethyl-2,2-diphenylvalerate (SKF8742). P450-selective inhibitors indicated CYP3As catalyzed this reaction, and the deethylation rate correlated best with the CYP3A activity across a range of human liver microsomes. SKF525A and its metabolite and primary amine analog all inhibited CYP2B6-, CYP2C9-, CYP2C19-, CYP2D6-, and CYP3A-selective reactions to varying degrees but had little effect on CYP1A2, CYP2A6, and CYP2E1 reactions. Only the inhibition of CYP3A showed major enhancement when the inhibitors were preincubated with NADPH-fortified microsomes, and the extent of metabolic intermediate (MI) complex formation approximated typical CYP3A content. Two "lost with time" SKF525A derivatives devoid of the ethylamine moiety, 2,2-diphenylpropylethanol (SKF-Alcohol) and 2,2-diphenylpropylacetic acid (SKF-Acid) did not form an MI complex and were identified as selective inhibitors of CYP2C9. Although without detectable metabolism, their CYP2C9 inhibition fitted best with a competitive mechanism. Thus, not all the human P450s are inhibited by SKF525A and related compounds, and the mechanisms contributing to those that are inhibited vary with the isoform. P450 MI-complex formation only seems to play a role with CYP3As.
A decade before cytochrome P450 (P450) was identified and characterized Sato, 1962, 1964a,b) , inhibition of its reactions by SKF525A 1 had been noted. SKF525A potentiated the barbiturate sleeping time by blocking barbiturate oxidative metabolism Cook et al., 1954) . In the subsequent years, it became one of the most widely used P450 inhibitors, even though some facets of its inhibitory activity were not fully comprehended at the time of its use. These features include its metabolism to inhibitory N-dealkylated metabolites (Anders et al., 1966) and the ability during its metabolism to form "metabolic-intermediate" (Franklin, 1981) and "quasi-irreversible" (Ortiz de Montellano and Reich, 1986) heme complexes with P450 (Schenkman et al., 1972; Buening and Franklin, 1974) , resulting in inhibition. Often unrecognized were inhibitory properties of portions of the molecule divorced from the aminoethyl moiety. This latter property had been revealed in the earliest structure activity relationship studies associated with SKF525A inhibition, the molecules being termed SKF-Acid (2,2-diphenylpropylacetic acid) (Cooper et al., 1954) and SKF-Alcohol (2,2-diphenylpropylethanol) (La Du, 1962) .
Not surprisingly, all the earlier studies on inhibition by SKF525A were performed in laboratory animals and in laboratory animal liver preparations (Netter, 1980) . When human liver microsomes and expressed human P450s became readily available, the interest and emphasis for P450 inhibitor studies had shifted toward inhibitors selective for individual family members, and few studies seem to have investigated the inhibitory effects of SKF525A and its derivatives on human P450-dependent reactions. Later, limited studies with human P450s expressed in HepG2 cells indicated that SKF525A inhibited all the family members, although with greatest effect toward CYP2D6, CYP2B6, and CYP3A5 (Ono et al., 1996) . In human liver microsomes, SKF525A was most inhibitory toward CYP2D6-, CYP2C19-, and CYP3A-catalyzed reactions (Ono et al., 1996) . In studies with baculovirus-expressed enzymes (Emoto et al., 2003) and human liver microsomes (Emoto et al., 2005) , a similar rank order was seen, although the degree of inhibition of CYP3A-catalyzed reactions showed considerable variation among the substrates/reactions used. Preincubation of SKF525A with human liver microsomes and NADPH decreased the inhibitory activity toward CYP2D6 and CYP2C19, variously either decreased or increased inhibitory activity toward CYP3A (depending on the substrate examined), and increased the inhibitory activity toward CYP1A2. Enhanced inhibition associated with preincubation of inhibitor with NADPH-fortified microsomes is an indication of possible mechanism-based inactivation.
The mechanism-based inactivation of SKF525A and structurally related compounds would probably arise from the formation of P450 metabolic-intermediate (MI) complexes, complexes that arise from interactions of the metabolically generated nitrosoalkane species with the heme of the cytochrome. These complexes can be detected by their characteristic difference spectrum, and in early animal studies, using different P450 inducers, it became obvious that all the P450s were not equal in their ability to form such complexes, those induced by phenobarbital having greater proficiency than those induced by 3-methylcholanthrene (Buening and Franklin, 1974) . Spectral determination of MI complex formation from SKF525A and the secondary and primary amine analogs by human P450s seems not to have been investigated, although formation by therapeutic drugs of the likely same "MI-complex forming class" (Pershing and Franklin, 1982) has. Except for a recent study with nortriptyline, where recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 were shown equally able to form an MI complex (Polasek and Miners, 2008) , complex formation seems confined to CYP3A, where it has been identified with diltiazem (Jones et al., 1999; Ma et al., 2000; Mayhew et al., 2000; McConn et al., 2004) and N-desmethyl diltiazem (Mayhew et al., 2000) , fluoxetine (Mayhew et al., 2000) , nicardipine (Ma et al., 2000; McConn et al., 2004 ), verapamil (Ma et al., 2000 Wang et al., 2005) , and tamoxifen and N-desmethyltamoxifen (Zhao et al., 2002) . Neither CYP2D6 nor CYP2C9 is able to form MI complexes from diltiazem, nicardipine, or verapamil (Ma et al., 2000) . Because nortriptyline was among the early identified SKF525-type MI complex-forming compounds (Buening and Franklin, 1974) and seems to have properties outside of the other MI complex-forming agents with respect to human P450s, an investigation of the inhibitory properties of SKF525A and its secondary amine derivative and other related compounds toward human P450s was initiated and forms the basis of this report.
Materials and Methods
Commercially available human hepatic microsomes white, 63) ; HBI-227 (female, white, 77); HBI-229 (male, Hispanic, 50); HBI-232 (male, white, 74); HBI-233 (male, white, 50); Human Biologics Inc., Scottsdale, AZ and Celsis X008066 (25-donor mixed gender pool); Celsis In Vitro Inc., Baltimore, MD] were mixed in the ratio of 0.5:0.5:0.75:1:0.25:1, respectively, to serve as a universal source in which all the enzyme activities were sufficiently robust as to be accurately determined after any inhibition. Other human liver microsome samples from Human Biologics Inc. were used in studies correlating SKF8742 formation from SKF525A with CYP3A activity. Spectral determinations of MI complex formation were undertaken using HBI-112 and Celsis X008065 microsomes.
SKF525A, SKF8742, SKF26754, SKF2314 ("SKF-Acid"), SKF3093 ("SKFAlcohol"), and trimeprazine were gifts from Smith Kline and French Laboratories (Philadelphia, PA). The structures of SKF525A and related compounds are shown in Fig. 1 . P450 substrates, metabolic products, inhibitors, and high-performance liquid chromatography (HPLC) internal standards were purchased from Sigma-Aldrich (St. Louis, MO) except for 7-methoxyresorufin (Fluka, Buchs, Switzerland), S-mephenytoin and 4-hydroxymephenytoin (SAFC Corp., St. Louis, MO), and tranylcypromine (Acros Organics, Fairlawn, NJ). The P450-GloCYP2C9 Assay Kit (6Ј-deoxyluciferin hydroxylation) was purchased from Promega (Madison, WI).
The screen of eight isozyme-selective enzyme activity assays was performed at 1 mg of protein/ml (0.44 nmol of P450/ml) at 37°C and with excess (Ͼ1.5 mM) NADPH. Original references for the P450-selective assays are referenced in Franklin and Constance (2007) . Methoxyresorufin demethylation (CYP1A2), coumarin 7-hydroxylation (CYP2A6), 7-ethoxy-4-trifluoromethylcoumarin deethylation (CYP2B6), and 7-methyl-4-aminoethylcoumarin demethylation (CYP2D6) were kinetic fluorometric assays using excitation and emission wavelength pairs of 544/612 nm, 370/455 nm, 409/530 nm, and 405/480 nm, respectively. 6Ј-Deoxyluciferin hydroxylation activity (CYP2C9) used luminescence detection of the metabolite luciferin. The products of CYP2C19 (S-mephenytoin 4-hydroxylation), CYP2E1 (chlorzoxazone 6-hydroxylation), and CYP3A4/5 (testosterone 6␤-hydroxylation) activities were determined by HPLC of dichloromethane extracts of the incubations spiked with internal standards (nitrazepam, zoxazolamine, and 11␤-hydroxytestosterone, respectively) and quantified from integrated peak area and comparison with authentic metabolite standards. All the HPLC separations were performed on a Supelco Discovery C18 column (250 ϫ 4.6 mm, 5 mm) with elution flow rates of 1 ml/min of acetonitrile (CYP2E1, CYP3A4/5) or acetonitrile/methanol (CYP2C19) gradients. All the chromatography used UV absorbance detection: 225 nm (CYP2C19), 280 nm (CYP2E1), and 236 nm (CYP3A4/5). Diclofenac 4-hydroxylation (a second CYP2C9-selective assay) used nitrazepam as an internal standard; the incubation was extracted with ethyl acetate; and the chromatography used an acetonitrile gradient and 268-nm absorbance detection.
SKF525A and its metabolites and derivatives were determined by HPLC after ethyl acetate extraction of microsomal incubations. Compounds were separated using isocratic elution with acetonitrile/40 mM phosphate buffer, pH 7.4 (53:47), and detected by absorbance at 225 nm. Trimeprazine was used as an internal standard. For SKF-Acid determinations, a 0 to 100% acetonitrile (balance 0.1% trifluoroacetic acid) gradient was employed, and nitrazepam was used as the internal standard.
Results
Secondary and tertiary alkylamines are susceptible to oxidative N-dealkylation by P450. Incubation of SKF525A (tertiary amine) and SKF8742 (secondary amine) with human hepatic microsomes and NADPH for 15 min revealed that only the former is deethylated in vitro (Table 1) . At 100 and 33 M, 33 and 48%, respectively, of the SKF525A could be detected as the mono-deethylated metabolite with no evidence of a primary amine. With incubations to which the SKF8742 was added, it could be fully recovered, confirming the absence of onward metabolism (N-deethylation) to the primary amine. For the primary amine, there was a ϳ13% loss in recovery from microsomal incubations, but there was no evidence of additional peaks in the HPLC chromatograms of the ethyl acetate extract. 
Downloaded from
The metabolism of SKF525A to SKF8742 was investigated further using P450-selective inhibitors (Table 2 ) and by correlation with enzyme activities of individual human liver microsomal samples (Fig.  2) . Only a single inhibitor, ketoconazole, resulted in a major decrease in the deethylation reaction, 35% at the determined IC 50 concentration for testosterone 6␤-hydroxylation (0.03 M) and 78% at a 10-fold higher concentration (0.3 M). When SKF8742 formation was plotted against the supplier P450-selective activity of human liver samples (n ϭ 12), the best linear correlation was with CYP3A, for which a correlation coefficient (R) of 0.815 was obtained (Fig. 2) . Correlation coefficients for other supplied P450 activities were 0.45, 0.53, 0.75, 0.22, 0.20, 0.14, and 0.32 for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP2E1, respectively.
Investigation of the ability of SKF525A, as well as the secondary and primary amine derivatives, to inhibit eight P450-selective reactions revealed that inhibition extended beyond the ability of the compounds to undergo a deethylation reaction (Table 3) . Three reactions, those for CYP1A2, CYP2A6, and CYP2E1, did not show substantial inhibition (Ͻ30% at 100 M) with any compound, and in some instances, slight activation was observed, most often with methoxyresorufin demethylation (CYP1A2). Of the remaining reactions, the rank order of inhibition varied with the compound. With SKF525A, 7-methyl-4-aminoethyl coumarin demethylation (CYP2D6) was most inhibited, followed by CYP2C9, CYP2C19, and CYP2B6 reactions. Testosterone 6␤-hydroxylation (CYP3A4/5) was the least inhibited of the five, particularly noticeable at the lower concentration evaluated in common (33 M). Inhibition of the remaining five reactions by SKF8742 revealed a rank order of inhibition similar to SKF525A with one exception. Whereas CYP2D6 was the most inhibited, followed by CYP2C9, the inhibition of CYP3A by SKF8742 was similar to the inhibition of CYP2C9, rather than being the least inhibited. With the primary amine (SKF26754), the CYP2C9 reaction, not the CYP2D6 reaction, was the most inhibited. The ability of SKF26754 to inhibit CYP3A also exceeded its ability to inhibit CYP2D6.
The relative inherent inhibitory properties of the primary and secondary amine compounds are different among the P450s, with the 2. NADPH-fortified human liver microsomes (a 1 mg/ml mix of six commercial preparations) were incubated with SKF525A (100 M) for 15 min. The metabolism to SKF8742 was determined and plotted against the supplier CYP3A activity (testosterone 6␤-hydroxylation; picomole per milligram per minute). Each value is the mean of two independent incubations.
TABLE 3
The inhibition of P450 isoform-selective reactions by SKF525A and N-deethylated derivatives in human liver microsomes NADPH-fortified human liver microsomes (a 1 mg/ml mix of six commercial preparations) were incubated with P450-selective substrates at the concentrations of the inhibitors indicated. Each value is the mean of two independent incubations with the superscript indicating the Ϯrange (to the nearest integer). primary amine being less (CYP2D6), similar (CYP2B6, CYP2C19), or more (CYP2C9, CYP3A) inhibitory than the secondary amine. In comparing inhibitory potencies of the primary and tertiary amines for the most inhibited reactions, SKF26754 was more inhibitory and SKF525A was less inhibitory toward CYP3A and CYP2C9, but the situation was dramatically reversed for CYP2D6. Examination of the inhibitory effects of SKF525A derivatives lacking the amine portion, SKF-Acid and SKF-Alcohol, revealed them to be selective inhibitors of CYP2C9 (Table 4 ). The potency of the SKF-Alcohol was similar to SKF26754, the most inhibitory amine-containing derivative for this reaction, whereas SKF-Acid was an order of magnitude more potent. Therefore, the inhibition kinetics of SKF-Acid toward CYP2C9 was determined (Fig. 3) , and the data were found to fit best with a competitive mechanism. For 6Ј-deoxyluciferin hydroxylation, a K i value of 0.56 M could be derived. From microsomal incubations with SKF-Acid, 90% of the SKF-Acid was recoverable by ethyl acetate extraction, independent of the duration of incubation and whether NADPH was also present, and under no conditions were additional peaks present in the HPLC chromatogram. The low K i value toward 6Ј-deoxyluciferin hydroxylation prompted further investigation using a second CYP2C9 substrate, diclofenac (Table 5) . Again there was an order of magnitude difference in the IC 50 values of SKF-Acid and SKF-Alcohol, and the value for the latter was similar to that for SKF26754, the most inhibitory aminecontaining derivative. As with 6Ј-deoxyluciferin hydroxylation, the inhibition kinetics of SKF-Acid on diclofenac 4-hydroxylation also correlated best with a competitive mechanism, but the K i value of 2.3 M was considerably higher (Fig. 3) . It was noted that the IC 50 value of sulfaphenazole for this reaction (2.9 M) was also higher than that for 6Ј-deoxyluciferin (0.2 M).
P450 Isoform
Increased inhibitory activity associated with preincubation of inhibitor with NADPH-fortified microsomes is suggestive of mechanism-based inactivation, a phenomenon that includes changes associated with the inhibition seen with P450 MI complex formation. Enhanced inhibitory activity with 15 min of preincubation is seen with SKF525A derivatives, although it was highly enzyme-specific (Tables  6 and 7 ; Fig. 4) . When examined for P450-selective activities showing little or no inhibition in the absence of preincubation, preincubation resulted in little or no change in inhibition (Ͻ20%) ( Table 7) . When examined for five P450-selective activities showing considerable inhibition in the absence of preincubation, major increases in inhibition with preincubation were seen only for the CYP3A4/5 reaction, and this occurred with all three amine-containing compounds: SKF26754, 
TABLE 5
The inhibition of diclofenac hydroxylation (CYP2C9) by SKF525A derivatives in human liver microsomes NADPH-fortified human liver microsomes (1 mg/ml of a mix of six commercial preparations) were incubated with diclofenac (50 M), and the concentrations of the inhibitors are indicated. Each value is the mean of two independent incubations with the superscript indicating the Ϯrange (to the nearest integer). 
Inhibitor

The inhibition of P450 isoform-selective reactions by SKF-Acid and SKF-Alcohol
NADPH-fortified human liver microsomes (a 1 mg/ml mix of six commercial preparations) were incubated with P450-selective substrates and the concentrations of the inhibitors indicated. Each value is the mean of two independent incubations with the superscript indicating the Ϯrange (to the nearest integer). (Table 5) . For all three inhibitors, inhibition of ϳ60% in the absence of preincubation was typically increased to around 90% with preincubation, and inhibition around 25% (at lower inhibitor concentrations) was increased to ϳ80%. Increased inhibition with preincubation toward CYP3A4/5 was not seen for either SKFAcid or SKF-Alcohol, the derivatives lacking an amine moiety. Spectrophotometric examination of microsomes for MI complex formation from SKF525A and related compounds revealed that in contrast to SKF26754, SKF8742, and SKF525A, SKF-Acid produced no detectable increase in absorbance at 452.5 nm, the absorbance maximum of MI complexes, when incubated with NADPH-fortified human liver microsomes (Fig. 5) . Because SKF8742 was more inhibitory than SKF525A toward CYP3A4/5 (Table 3) , formation of the secondary amine metabolite during the preincubation period would contribute to enhanced inhibition seen for SKF525A. The extent to which it could contribute was evaluated by examining the inhibition of CYP3A4/5 activity without preincubation by combinations of the parent and metabolite in proportion to the extent of metabolism (Table 1) . At 33 M, consisting of 17 M SKF525A and 16 M SKF8742, testosterone 6␤-hydroxylation was inhibited 61%, and at 100 M consisting of 70 M SKF525A and 30 M SKF8742A, the inhibition was 70%; 38 and 14% gains in inhibition, respectively, over SKF525A alone (Table 3) .
P450
Discussion
SKF525A and its N-desethyl and N-didesethyl derivatives are inhibitory, to differing extents, toward selective reactions for CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5 and had little, if any, inhibitory action toward CYP1A2-, CYP2A6-, and CYP2E1-selective reactions. Only the inhibition of CYP3A4/5 was markedly enhanced The changes in inhibition associated with preincubation of SKF525A and related compounds by NADPH-fortified human liver microsomes NADPH-fortified human liver microsomes (1 mg/ml of a mix of six commercial preparations) were incubated with the inhibitors at the concentrations shown for 15 min before the addition of P450-selective substrates. Each value is the mean of two independent incubations.
The subscript shows the percentage inhibition following preincubation, and an ЉaЉ following the number indicates activation rather than inhibition. The percentage change was calculated by subtracting the percentage inhibition without preincubation (from Table 3 ) from this subscript number.
P450 Isoform
Percentage 
The changes in inhibition of CYP1A2-, CYP2A6-, and CYP2E1-selective activities associated with the preincubation of SKF525A and related compounds by NADPH-fortified human liver microsomes NADPH-fortified human liver microsomes (a 1 mg/ml mix of six commercial preparations) were incubated with the inhibitors at the concentrations shown for 15 min before the addition of P450-selective substrates. Each value is the mean of two independent incubations. The subscript shows the percentage inhibition following preincubation, and an ЉaЉ following the number indicates activation rather than inhibition. The percentage change was calculated by subtracting the percentage inhibition without preincubation (from Tables 3 and 4 ) from this subscript number.
Percent Change in Inhibition with Preincubation
by preincubation of the inhibitors with NADPH-fortified microsomes.
With human liver microsomes, SKF525A metabolism only proceeded as far as the N-desethyl derivative, and CYP3A seemed to be the lone P450 responsible for this N-deethylation. SKF525A derivatives lacking the aminoethyl moiety were selective inhibitors of CYP2C9, and this inhibition was not enhanced with preincubation, nor, by spectrophotometric observation, did they form MI complexes. Taken together, these findings underscore that the inhibition of human P450s by SKF525A and related compounds is complex and involves several mechanisms, and P450-MI complex formation only plays a role with CYP3A. The inhibition of multiple human P450s by the parent compound (SKF525A) has been observed previously (Ono et al., 1996; Emoto et al., 2005) . In human liver microsomes, SKF525A was most inhibitory toward CYP2D6-, CYP2C19-, and CYP3A4/5-catalyzed reactions (Ono et al., 1996) . Limited studies with human P450s expressed in HepG2 cells indicated that 300 M SKF525A inhibited all the family members, although with greatest effect toward CYP2D6, CYP2B6, and CYP3A5 (Ono et al., 1996) . In studies with baculovirus-expressed enzymes (Emoto et al., 2003) and human liver microsomes (Emoto et al., 2005) , a similar rank order was seen, although the degree of inhibition of CYP3A-catalyzed reactions showed considerable variation among the substrates/reactions used. Among the CYP3A-catalyzed reactions, testosterone 6␤-hydroxylation exhibited the lowest IC 50 (ϳ3 M), a value similar to that seen for CYP2C19 and 100-fold higher than for CYP2D6. Our studies reveal a similar 100-fold difference between inhibition of CYP3A and CYP2D6 (Table 3) with the inhibition of CYP2C9, CYP2B6, and CYP2C19 between the two. There was little SKF525A inhibition of CYP1A2-, CYP2A6-, and CYP2E1-catalyzed reactions.
Enhanced inhibition when inhibitors are preincubated with microsomes and NADPH before the addition of the P450-selective substrate can provide an indication of whether mechanism-based inhibition contributes to any inhibition observed. For alkylamines, mechanismbased inhibition probably arises from the formation of an MI complex, the result of the interaction of a nitroso intermediate with the heme. Spectrophotometric examination of microsomes incubated with NADPH and SKF26754, SKF8742, or SKF525A showed spectral changes characteristic of MI complex formation (Fig. 5) . Assuming an extinction coefficient of 65 mM Ϫ1 cm Ϫ1 for the complex (Franklin, 1974) , the amount of P450 in the MI complex for SKF8742 for the detection periods shown was ϳ0.1 nmol/mg, a value that would account for 20% (HBI-112) and 30% (Celsis X008065) of the total microsomal P450. These percentage values approximate the values commonly reported for the percentage of human liver P450 that is CYP3A (Shimada et al., 1994) .
Enhanced inhibition with preincubation could also arise if metabolites produced in the preincubation are more inhibitory than the parent compound. Comparison of the inhibitory effects of SKF8742, the demonstrated metabolic product of SKF525A (Table 1) , with those of the parent SKF525A indicates that for all except testosterone 6␤-hydroxylation (CYP3A4/5) the two compounds are of similar inhibitory potency, with a tendency for SKF8742 to be slightly less inhibitory (Table 3) . Toward CYP3As, SKF8742A is more inhibitory, and so generation of this metabolite during the preincubation also contributes to the enhanced inhibition observed for SKF525A. The inhibition seen with relevant combinations of SKF525A and SKF8742 without preincubation was indeed greater than seen with SKF alone, 61 versus 23% at 33 M and 70 versus 56% at 100 M, but was less than the inhibition observed with SKF525A preincubation conditions (87 and 90% at the two concentrations, respectively). Thus, the more inhibitory secondary amine metabolite only partially accounts for the enhanced inhibition seen with preincubation and SKF525A. SKF8742 does not undergo detectable [compound bound as the MI complex (0.1 M) accounts for less than 0.3% of the total at 33 M] loss from metabolism (Table 1) , so for this compound other inhibitory metabolite consideration is moot, and enhanced inhibition with preincubation can be attributed to mechanism-based effects.
The absence of a preincubation enhancement of inhibition for SKF8742 and SKF26754 with all the enzymes except CYP3A suggests that for all except CYP3A, the inhibition is also not dependent on conversion to an MI complex-forming nitroso derivative (Table 6) and is probably an inherent property of the unmetabolized molecule. A necessary structural feature for MI complex-independent inhibition of CYP2D6, CYP2B6, and CYP2C19 seems to be either the presence of an ethylaminoethyl/aminoethyl entity or the absence of a carboxyl group because without an ethylaminoethyl/aminoethyl entity or with a free carboxyl group present (SKF-Acid) (Table 4) , these enzymes are not inhibited. CYP2C9 is inhibited by all the compounds investigated, including SKF-Acid and SKF-Alcohol, suggesting that the lipophilic section of the molecule distal from either the ethylamino or acid/ alcohol entities contributes significantly to the inhibition of this particular enzyme. The greater potency of SKF-Acid as an inhibitor of CYP2C9 correlates with the selectivity of this enzyme for the oxidation of relatively small lipophilic anionic drugs (reviewed in Rettie and Jones, 2005) . The kinetics of inhibition showed a best fit to a competitive mechanism (Fig. 3) with K i values in the low micromolar range.
The active site of CYP3A seems to be the only one among the P450s investigated that is able to accommodate SKF525A in a manner that allows N-deethylation and for all the aminoethyl-containing derivatives in a manner that allows oxidation to a nitroso intermediate in sufficient proximity to the heme to form an MI complex. All three compounds showed major enhancement of inhibitory activity toward testosterone 6␤-hydroxylation with preincubation of inhibitor with NADPH-fortified microsomes (Table 5 ). An enhancement of inhibition of CYP3A reactions (nifedipine oxidation and midazolam 1Ј- hydroxylation) with preincubation had been shown for SKF525A previously (Emoto et al., 2005) , although in the same study, the opposite effect (an increase in IC 50 ) had been seen for testosterone 6␤-hydroxylation. In the present study, preincubation with SKF525A shows an enhancement of inhibition of this latter reaction with preincubation.
The degree of enhancement of inhibition seen with preincubation was inversely proportional to the extent of inhibition in the absence of preincubation, and this relationship held equally for SKF8742 and SKF26754 (Fig. 6) . The SKF525A inhibition was not included in this consideration because of the complicating N-deethylation to SKF8742 occurring during preincubation.
The present information with SKF525A and related compounds adds to the majority of the published data that MI complex formation from alkylamine compounds by human P450s seems to be an exclusive property of CYP3A. Therefore, it would be with drugs metabolized by this enzyme that one might look in vivo for inhibitory effects of alkylamine compounds that extend temporally beyond the presence of the drug, a consequence of the mechanism-based inhibition from P450-MI complex formation. FIG. 5 . P450-MI complex formation by spectrophotometry was documented with human liver microsomes (1 mg/ml) with 33 M substrate (SKF compounds) at 25°after the addition of NADPH. Top, with HBI-112 microsomes (P450 ϭ 0.47 nmol/mg) and SKF8742, the reduced minus oxidized spectrum of the microsomes was successively recorded at 5, 13, 21, and 29 min after the addition of NADPH. Bottom, the kinetics of P450-MI complex formation (absorbance at 452.5 nm) from four SKF525A-related compounds after NADPH addition was recorded for Celsis X008065 microsomes (P450 ϭ 0.32 nmol/mg). 
